INDIA –Medtronic, a global leader in healthcare technology has announced the launch of MiniMed 780G system in India.
MiniMed 780G, a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in patients aged seven to eighty.
The system automates the delivery of both basal insulin and correction boluses every five minutes, making it easier for diabetics to avoid highs and lows.
The MiniMed 780G system personalizes glucose goals with an adjustable target setting as low as 100 mg/dL — lower than any other advanced hybrid closed-loop system — and is designed to help stabilize blood sugar levels and improve glucose control.
The system is part of a new Medtronic insulin pump portfolio that includes smartphone connectivity via Bluetooth technology.
Users and their care partners can now view real-time glucose data and trends on compatible iOS and Android smartphones via apps.
Furthermore, healthcare providers will find that managing patients on the system is simple because there are only a few settings that need to be tweaked to make the technology work optimally.
Patients who took part in a clinical study said that the MiniMed 780G system “made life with diabetes and control so much easier” and “significantly easier.”
The first patient in India to receive this therapy was through Dr V. Mohan, chairman and chief of diabetology, Dr Mohan’s Diabetes Specialties Center, Chennai.
India has the world’s second-highest number of children and adolescents aged 0 to 19 years with type 1 diabetes (171,300), and it is home to the majority of children and adolescents with diabetes in Southeast Asia.
The estimated annual number of new cases of type 1 diabetes in children and adolescents (0-14 years) is 15,900.
Unfortunately, very few people with type 1 diabetes achieve HbA1c & lt;7% and Time in Range & gt;70% diabetes treatment goals.
HbA1c is the average blood sugar level over the previous two to three months, and Tim in Range (TIR) is the amount of time a person spends in the desired glucose range.
The range will vary depending on the person, but general guidelines suggest starting with a range of 70 to 180 mg/dl.
The treatment goals for type 1 diabetes include maximizing Time in Range and avoiding long-term complications, which is a constant juggling act as people try to manage insulin levels while going about their daily lives.
Managing blood glucose variables, administering correction boluses as needed, and effectively counting and tracking carbohydrates are all daunting tasks for diabetics because they serve as a constant reminder of the disease.
However, advanced technologies such as the MiniMed 780G system can help to alleviate some of that burden.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
